Introduction
CD95 (Fas/Apo-1) is a cell surface receptor protein belonging to the tumor necrosis factor (TNF) superfamily.
1,2 Crosslinking with CD95 ligand or monoclonal antibodies induces programmed cell death. 3, 4 The CD95 receptor/ligand system plays a pivotal role in the homeostasis of the immune system. 5 Indeed, CD95-mediated apoptosis is involved in T cell cytotoxicity and in activation-induced cell death of T lymphocytes. [6] [7] [8] Concerning the human B cell immune response, the role of CD95 is underlined by the development of an autoimmune lymphoproliferative syndrome in humans with defective CD95-mediated apoptosis. 9, 10 Moreover, an essential role for in vivo CD95 ligation in the expansion of antigen reactive B cells and the elimination of self-reactive and tolerant B cells has recently been described. 11 CD95 expression is found on a broad range of cells, including activated T and B cells, 3 virally transformed lymphoblastoid cells and various lymphoid malignancies such as B non-Hodgkin's lymphomas (NHL), Hodgkin disease and peripheral T cell lymphomas. [12] [13] [14] Malignant NHL are derived from a clonal expansion of B cells arrested at different stages of differentiation. 15 Frequent CD95 expression has been reported in NHL 12, 13 but the possible role of CD95 in growth regulation of lymphoid neoplasms has not been fully investigated. However, our laboratory has recently shown that fresh tumoral B cells from NHL, expressing CD95, are resistant to CD95-mediated apoptosis. 16 In mammalian cells, multiple caspases, a growing family of cysteine proteases, are activated during CD95-mediated apoptosis. [17] [18] [19] Triggering of apoptosis by CD95 ligation results in the recruitment of a set of proteins that includes FADD/MORT-1 and caspase-8 (FLICE) to the receptor forming a complex of proteins, the death-inducing signalling complex (DISC). 20 Recruitment of caspase-8 to the DISC leads to its proteolytic activation 21 which initiates activation of additional caspases [22] [23] [24] leading to apoptosis. Caspase-3, which is functionally similar to the cell death protein CED-3 from the nematode C. elegans, seems to play an important role in the effector pathway of the apoptotic response. 25 Proteolytic processing and activation of caspase-3 have been described during CD95-mediated apoptosis 18 and in response to certain apoptotic inducers such as staurosporine. 26, 27 Regulation of apoptosis by members of the Bcl-2 family has been widely reported. Cell death antagonists like Bcl-2 and Bcl-xL are potent inhibitors of apoptosis induced by irradiation, growth factor deprivation, or chemotherapeutic agents, 28 while cell death agonists like Bax, Bad, Bak or BID increase cellular susceptibility to apoptosis. 29 Recently, involvement of mitochondria in apoptotic processes has been demonstrated, 30 including for CD95-mediated apoptosis. 31 All mitochondrial activities in apoptosis can be blocked by overexpression of Bcl-2 or Bcl-xL. 29 However, the ability of Bcl-2/Bcl-xL to inhibit CD95-induced cell death remains controversial. 32 A new class of apoptosis inhibitor molecules, named cellular FLICE-inhibitory proteins (c-FLIP), which are structurally similar to caspase-8, has been described. 33 c-FLIP prevents caspase-8 activation at the DISC and thereby inhibits CD95-mediated apoptosis. Expression of c-FLIP has been described in melanoma and in human T cell lines which express CD95, but are resistant to CD95-mediated apoptosis. 33 The ability of c-FLIP to inhibit apoptosis remains controversial. Some studies have described it as a pro-apoptotic protein 34, 35 and others as an anti-apoptotic protein. 33, 34, 36 In the present study, we investigate the possible mechanisms of resistance to CD95-mediated apoptosis in tumoral B cells from NHL. We describe two B lymphoid cell lines, derived in our laboratory from non-Hodgkin's lymphoma, which show marked differences in sensitivity to CD95-induced apoptosis. While one cell line, B593, is highly sensitive to CD95-mediated apoptosis, the other, BR97, is completely resistant. This resistance was not due to alterations in the CD95 signalling pathway itself and was correlated to the constitutive expression levels of apoptotic inhibitor c-FLIP.
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Materials and methods
Establishment and culture of cell lines B593 and BR97
Cell lines B593 and BR97 were derived from the lymph nodes of two patients with B-NHL. Patient Co (diagnosed with follicular lymphoma subsequently transformed in to diffuse large cell lymphoma) and patient Ra (diagnosed with diffuse large cell lymphoma). 37 Nude mice were engrafted with fragments of malignant lymph nodes and transplantable tumors were obtained and passaged in vivo over 4 months. The B593 and BR97 cell lines were established in vitro from the tumoral cells. Cell lines were cultured in RPMI 1640 Glutamax medium supplemented with 15% heat-inactivated fetal calf serum for B593 cells, or with 10% heat-inactivated AO human serum for BR97 cells, 100 g/ml penicillin-streptomycin, 1.4 mM sodium pyruvate and 1.4 mM non-essential aminoacids (all reagents were from GIBCO BRL, Rockville, MD, USA). Cells were cultured at 37°C in a humidified 5% CO 2 atmosphere.
Drugs and chemical reagents
Stock solutions of cycloheximide (100 mM) and staurosporine (1 mM) in dimethylsulfoxide (DMSO) were stored at −20°C (Sigma-Aldrich, St Quentin Fallavier, France). Further dilution of drugs were made in culture medium just before use. Antihuman CD95 mAb (clone CH-11) was obtained from Immunotech (Marseille, France). In all experiments the final concentration of DMSO did not exceed 1/1000 (v/v), a concentration which was not toxic to the cells.
CD95 expression analysis
CD95 expression on cells was analyzed by flow cytometry. Briefly, 5 × 10 5 cells were incubated for 20 min at 4°C with PE-conjugated anti-CD95 mAb (DAKO, Trappes, France) and washed twice with phosphate-buffered saline (PBS). After two washings in PBS, immunostained cells were analyzed by flow cytometry on a FACScan cytometer (Becton Dickinson, NJ, USA). Non-specific staining was determined using a PE-conjugated IgG control mAb (Dako). Percentage of positive cells and mean fluorescence intensities (MFI) were recorded.
Induction and measurement of apoptosis
All cultures were performed in RPMI supplemented medium. Briefly, 5 × 10 5 B593 or BR97 cells/ml were treated with mAb CH-11 at different concentrations (0.01-10 g/ml) and time periods (4-72 h) at 37°C in humidified 5% CO 2 atmosphere. In some experiments, BR97 cells were treated with only cycloheximide (10 M) for 12-24 h or with cycloheximide (10 M) immediately before the addition of mAb CH-11 (1 g/ml) for 12-24 h. Both cell lines were incubated with staurosporine at 5 M for 4 to 18 h. To ensure an exponential growth, cells were resuspended in fresh medium 24 h before each treatment.
The apoptotic cells were quantified in each experimental condition by annexin V-fluorescein isothiocyanate (FITC)/ propidium iodide (PI) staining using the Apotest (Immunotech). As described, 38 treated or untreated cells (5 × 
Western blot analysis
B593 and BR97 treated or untreated cells were washed in PBS and lysed in lysis buffer (1% Triton X-100, 50 mM Tris-HCl pH 8, 150 mM NaCl, 5 mM EDTA) in the presence of protease inhibitors (1 mM PMSF, 100 M iodoacetamide, 10 M leupeptin) for 30 min at 4°C (all reagents were from Sigma). Cell debris were removed by centrifugation at 13 000 r.p.m. for 30 min at 4°C. We determined the protein concentration of clarified supernatants by the BCA Protein Assay Reagent kit (Pierce, IL, USA). For all analyses, identical amounts of protein were loaded per lane on 10%, 12% or 15% SDS-polyacrylamide gel. After electrophoresis, proteins were transferred to a PVDF membrane (Millipore, St Quentin-Yvelines, France) for 1 h at 100 V using a transfer buffer (15% methanol, 25 mM Tris base, 192 mM glycine). After blocking non-specific binding sites overnight with 5% non fat milk in TPBS (PBS, Tween 20 0.1%), the membranes were incubated for 2 h at room temperature with primary antibodies: rabbit polyclonal antiBax (Santa Cruz Biotechnology, CA, USA), rabbit polyclonal anti-Bcl-xL (Transduction Laboratories, CA, USA), anti-Bcl-2 mAb (DAKO), rabbit polyclonal anti-caspase-3 (Pharmingen, CA, USA), anti-PARP mAb (Zymed Laboratories, CA, USA), anti-caspase-8 mAb (Immunotech) and anti-actin mAb (Amersham Life Science, Les Ulis, France). Antiserum against human c-FLIP was kindly provided by Dr J Tschopp (Institute of Biochemistry, Epalingues, Switzerland). Antibody labeling was revealed using goat anti-rabbit or anti-mouse horseradish peroxidase-conjugated secondary antibodies (Jackson Immunoresearch, PA, USA), and was visualized using enhanced chemiluminescence (ECL) (Amersham).
DISC immunoprecipitation and analysis by Western blotting
The amount of DISC-associated FADD, FLICE/caspase-8 and c-FLIP was determined as described. 39 Briefly, 20 × 10 6 cells were either first stimulated with 1 g/ml anti-APO 1-3 (Alexis Biochemicals, CA, USA) for 30 min at 37°C and then lysed in lysis buffer (30 mM Tris, pH 7.5, 150 mM NaCl, 1 mM phenylmethylsulfonyl fluoride (PMSF) and 4 g/ml aprotinine, 1% Triton X-100, and 10% glycerol) or first lysed and then supplemented with 2 g/ml anti-APO 1-3 (unstimulated condition). The CD95 DISC was then precipitated for 3 h at 4°C with protein A-Sepharose (Amersham Pharmacia Biotech) with rotation. After immunoprecipitation the beads were washed three times with 500 l of lysis buffer. For Western blotting, immunoprecipitated proteins equivalent to 20 × 10 6 cells were separated by 12% SDS-PAGE and transferred to PVDF membrane (Millipore), blocked with 5% non fat milk in PBS, overnight at 4°C.
After washing in PBS/0.1% Triton 100-X the membrane was incubated with anti-caspase-8 mAb (Immunotech), with anti-FADD mAb (Immunotech) or with anti-c-FLIP mAb NF6 (kindly provided by Dr PH Krammer, German Cancer Research Center, Heidelberg, Germany). Blots were revealed using the HRP-coupled goat anti-mouse IgG1 and IgG2b antibodies (Southern Biotechnology Associates, AL, USA) diluted 1/1000 or 1/10 000 in 5% non-fat milk, PBS/0.1% Triton 100-X. The blots were developed with the enhanced chemiluminescence method (ECL) (Amersham).
Measurement of caspase-8 and caspase-3 like activities
1 × 10 6 B593 and BR97 cells were plated in 24-well plates in 2 ml of appropriate culture media. Following treatment, cells were washed in RPMI and lysed for 10 min at 4°C in 50 l lysis buffer according to the manufacturers' instructions (ApoAlert CPP32/Caspase-3 or FLICE/Caspase-8 fluorescent assay kits, Clontech Laboratories, CA, USA). Then, 50 l reaction buffer and 5 l of DEVD-AFC or IETD-AFC substrates were added and the reaction was incubated at 37°C for 1 h in microcentrifuge tubes. Fluorescence was read on a fluorimeter (Jobin YVON Spectrofluo JY3D) at an excitation wavelength of 380 nm and emission wavelength of 508 nm.
Results
Establishment and characterization of cell lines B593 and BR97
Stable cell lines B593 and BR97 were obtained after transplantation of lymph nodes from two patients with B-NHL into nude mice. As shown in Table 1 
Expression of CD95 and differential sensitivity to CD95-mediated apoptosis in cell lines B593 and BR97
The expression of CD95 receptor in B593 and BR97 cells was analyzed by flow cytometry using the PE-conjugated anti-CD95 mAb (Figure 1 ). Both cell lines were positive for CD95 expression. Indeed, more than 95% of cells expressed CD95 and its expression was higher in BR97 cells compared to B593 cells (MFI of 99 and 35 respectively). Sensitivity of cell lines B593 and BR97 to CD95-mediated apoptosis was studied using the CH-11 agonistic anti-CD95 mAb at several doses and incubation times. Apoptotic cells were measured by flow cytometry using annexin V-FITC binding in combination with propidium iodide (PI) staining. As shown in Figure 2 , B593 cells were CD95-sensitive while BR97 were CD95-resistant. Incubation of B593 cells with doses as low as 0.01 g/ml of anti-CD95 mAb CH-11 for 18 h induced 41% apoptotic cells (Figure 2a ). In contrast, only 1% apoptotic cells were detected in the BR97 cell line at higher doses of anti-CD95 mAb CH-11 (1 g/ml) during the same time period (Figure 2c ). Resistance of BR97 cells to CD95-mediated apoptosis was observed even with doses of anti-CD95 mAb CH-11 as high as 10 g/ml and during prolonged incubation times up to 72 h (data not shown). In further experiments, CD95 stimulation of BR97 cells was always performed at 1 g/ml of CH-11 mAb during 18 h. As indicated in Materials and methods, optimal culture conditions for cell lines B593 and BR97 were 15% FCS and 10% HS, respectively. We observed that sensitivity of B593 cells to CD95-mediated apoptosis was essentially similar in both serums (Figure 2a and b) . However, in 10% HS specific apoptosis was 26% while the number of secondary necrotic cells PI+ was 38% compared to 18% in FCS. In summary, the two cell lines express CD95 receptor significantly, but show a substantially different sensitivity to CD95-induced apoptosis.
Absence of caspase-8 and caspase-3 activation in CD95-stimulated BR97 cells
To analyze whether resistance of BR97 cells to CD95-mediated apoptosis resulted from major abnormalities in intracellular mechanisms of apoptosis, we examined the capacity of staurosporine, a broad range protein kinase inhibitor, to induce cell death in BR97 compared to B593 cells. Both cell lines were treated with staurosporine (5 M) for different incubation times, and we quantified apoptosis by annexin V-FITC and PI staining. Staurosporine elicited cell death in both cell lines, but B593 cells were significantly more sensitive than BR97 cells. As shown in Figure 3a , 70% of B593 cells had undergone apoptosis following 4 h of staurosporine treatment, whereas cell death was undetectable in BR97 cells under similar conditions (data not shown). However, when incubation time was prolonged to 18 h staurosporine induced 35% apoptotic cells in the BR97 cell line (Figure 3b) . Thus BR97 cells were resistant to CD95-mediated apoptosis and moderately sensitive to staurosporine-induced apoptosis.
We next analyzed PARP cleavage and caspase-3 activation in response to CD95 stimulation or staurosporine treatment in the two cell lines. Activation of caspase-3 has been described in both CD95 and staurosporine-induced apoptosis. 26 Western blot analysis (Figure 4a ) of whole cell lysates from B593 cells, treated with anti-CD95 mAb CH-11 (0.01 g/ml) for 18 h showed cleavage of the 116 kDa PARP substrate into the Caspase-3 activation is induced by staurosporine and not by CD95-stimulation in BR97 cells. (a) Western blot analysis of PARP cleavage, procaspase-3 and active caspase-3 (p17 fragment) in B593 and BR97 cells following anti-CD95 and staurosporine stimulation. B593 cells were cultured in medium alone (−), incubated with 0.01 g/ml anti-CD95 mAb (CH11) for 18 h, or incubated with 5 M staurosporine (STS) for 4 h. BR97 cells were cultured with medium alone (−), with 1 g/ml of anti-CD95 mAb (CH11) for 18 h or with 5 M staurosporine (STS) for 18 h. Whole lysates of B593 and BR97 untreated or treated cells, were separated by 10% or 15% SDS-PAGE and examined by immunoblot using anti-PARP monoclonal antibody and anti-caspase-3 polyclonal antibody. Positions of uncleaved (116 kDa) and cleaved (85 kDa) PARP, the 32 kDa precursor (p32) and the active form (p17) of caspase-3 are indicated. (b) Analysis of caspase-3 like activity using the fluorogenic specific substrate (DEVD-AFC) in B593 () and BR97 (a) cells incubated with anti-CD95 mAb (CH11) or staurosporine (STS) under the same conditions described above. The value of caspase-3 like activity in the untreated cells was normalized as one-fold increase. characteristic 85 kDa fragment and cleavage of the 32 kDa procaspase-3 into 17 kDa active subunit (Figure 4a ). In contrast, PARP substrate and procaspase-3 remained uncleaved in anti-CD95 mAb CH-11 treated BR97 cells (1 g/ml, 18 h). However, treatment of B593 and BR97 cells with staurosporine (5 M) at incubation times that elicited apoptosis (4 and 18 h respectively) did induce cleavage of PARP and procaspase-3 ( Figure 4a ). In addition, the decline in procaspase-3 levels corresponded with the appearance of the active p17 subunit. These results were confirmed when caspase-3 activation was analyzed in both cell lines using the specific fluorogenic substrate DEVD-AFC (Figure 4b) . A significant increase in caspase-3 like proteolytic activity was detected in B593 cells following CD95 or staurosporine treatment (three-
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Figure 5
Caspase-8 activation is induced by staurosporine, but not by CD95 stimulation in BR97 cells. (a) Western blot analysis of procaspase-8 processing in B593 and BR97 cells following anti-CD95 or staurosporine stimulation. B593 and BR97 cells were incubated with either anti-CD95 mAb CH11 or with staurosporine (STS) under the same conditions described in Figure 4 . Extracts from cells cultured with medium alone are used as control (−). Whole cell lysates were electrophoresed on a 10% SDS-PAGE and were immunoblotted with anti-caspase-8 mAb. Position of procaspase-8 (55 kDa) is indicated. Actin monoclonal antibody was used to check gel loading. (b) Analysis of caspase-8 like activity using the fluorogenic specific substrate IETD-AFC in B593() and BR97 (a) cells incubated with anti-CD95 mAb (CH11) or staurosporine (STS) under the same conditions described in (a). The value of caspase-8 like activity in the untreated cells was normalized as one-fold increase. and five-fold increase, respectively). In contrast, in BR97 cells, no caspase-3 like activity was induced by CD95 stimulation while a significant increase was detected in staurosporinetreated cells (2.
5-fold increase).
To further analyze the CD95 signalling pathway in the two cell lines, we determined the functional status of caspase-8 by both immunoblotting and using the specific fluorogenic substrate IEVD-AFC. Western blot analysis revealed a marked decrease of caspase-8 proenzyme levels in B593 cells stimulated either by anti-CD95 mAb CH-11 or by staurosporine (Figure 5a ). In contrast, in CD95-stimulated BR97 cells, the level of caspase-8 proenzyme remained unchanged while it significantly decreased when these cells were treated with staurosporine ( Figure 5a ). Decline in procaspase-8 levels, which indicates processing of the protein, strictly correlated with an increase in caspase-8 like activity observed using the specific fluorogenic substrate IEVD-AFC (Figure 5b ). Indeed, CD95 or staurosporine-stimulated B593 cells displayed a high increase in caspase-8-like activity (three-and six-fold, respectively) while a significant increase (three-fold) was elicited only in staurosporine-treated, but not in CD95-stimulated BR97 cells.
Therefore, the observed activation of caspases-8 and -3, in staurosporine-treated BR97 cells, indicates that these caspases are functional in these cells. Furthermore, the absence of cas-
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Leukemia pase-8, an upstream caspase, and caspase-3 activation, in CD95-stimulated BR97 cells, suggests a blockage of CD95 pathway in BR97 cells which may be proximal to the receptor.
Protein synthesis inhibition restores sensitivity to CD95-mediated apoptosis in BR97 cells
It has been reported that the inhibition of protein synthesis can increase the sensitivity to CD95-mediated apoptosis in lymphoid cell lines. 40 We therefore tested whether the effect of cycloheximide, a protein synthesis inhibitor, could restore sensitivity to CD95-induced apoptosis. BR97 cells were incubated with anti-CD95 mAb CH-11 (1 g/ml) in the presence of cycloheximide (10 M) for 18 h. Under these conditions, CD95 stimulation induced 34% apoptosis in BR97 cells ( Figure 6) .
Furthermore, conversion of BR97 cells from resistant to sensitive by cycloheximide, correlated with PARP cleavage and caspase-3 activation as detected by immunoblot analysis (Figure 7a ) and using the substrate specific fluorescent assay (Figure 7b ). CD95 stimulation of BR97 cells (with anti-CD95 mAb CH-11), treated with protein synthesis inhibitor also induced a significant increase in caspase-8 like activity (3.5-fold), as detected by fluorogenic specific substrate (Figure 7b ). Caspase-8 activation was correlated with a decrease in the procaspase-8 protein levels as revealed by immunoblotting (Figure 7a) . Only a weak activation of both caspase-8 and caspase-3 was induced by cycloheximide alone, in BR97 cells.
Therefore, treatment of BR97 cells with cycloheximide, restores sensitivity to CD95-mediated apoptosis which is mediated by caspase-8 and caspase-3 activation. Taken together, these results not only indicate the integrity of the CD95 signalling pathway in the CD95 resistant cell line, but
Figure 6
Inhibition of protein synthesis restores CD95-mediated apoptosis in BR97 cells. BR97 cells were incubated with cycloheximide (CHX) (10 M) with or without anti-CD95 mAb (1 g/ml) for 18 h (CHX + CH11). Induction of apoptosis was analyzed by double staining with annexin V-FITC/PI using flow cytometry. Numbers within dot plots represent the percentage of viable, apoptoic (early and late) and necrotic cells. also suggest that resistance to CD95-mediated apoptosis may result from the synthesis of one or more inhibitory factors.
Resistance to CD95-mediated apoptosis in BR97 cells is correlated to c-FLIP expression level
The above results suggest that CD95-resistant BR97 cells are probably synthesizing inhibitors. To address this possibility, the expression levels of apoptosis inhibitor c-FLIP and of members of the Bcl-2 family (Bcl-xL, Bcl-2 and Bax) were examined in both cell lines by immunoblotting using specific antibodies. We used the T cell line, Jurkat, and the B cell line, Raji, as controls for CD95-positive and CD95-sensitive cells.
As shown in Figure 8a , BR97 cells constitutively expressed high levels of c-FLIP whereas expression of this protein was very low in B593 cells. Furthermore c-FLIP expression was also significantly lower in CD95-sensitive cell lines Jurkat and Raji. Constitutive high level expression of apoptotic inhibitor Bcl-xL was observed in BR97 cells compared to B593 cells.
Figure 7
Activation of both caspase-3 and caspase-8 in CD95-stimulated BR97 cells treated with cycloheximide. (a) Western blot analysis of PARP cleavage, procaspase-3, active caspase-3 (p17 fragment) and procaspase-8 in BR97 cells incubated with medium culture alone (−), cycloheximide at 10 M (CHX), anti-CD95 mAb at 1 g/ml (CH11) or anti-CD95 mAb and cycloheximide (CHX + CH11) under the same conditions, for 18 h. Whole lysates of BR97 cells (15 or 30 g/lane) were separated by 10% or 15% SDS-PAGE and examined by immunoblot, using anti-PARP mAb, anti-caspase-3 polyclonal antibody and anti-caspase-8 mAb. (b) Analysis of caspase-3(a) and caspase-8 (a) like activities using the fluorogenic specific substrates DEVD-AFC and IETD-AFC, respectively. BR97 cells were treated with cycloheximide (CHX), with or without anti-CD95 mAb (CH11), under the same conditions described in (a). The value of caspase-3 and caspase-8 like activities in the untreated cells was normalized as onefold increase.
A higher level of Bax protein expression was detected in B593 cells compared to BR97 whereas similar expression levels of Bcl-2 were observed in both cell lines.
We next studied whether protein synthesis inhibition by cycloheximide could modify the expression level of the apoptotic inhibitor c-FLIP in CD95-resistant BR97 cells. Analysis by immunoblotting showed a strong decrease of c-FLIP levels within 18 h (Figure 8b) , the time at which cycloheximide restored sensitivity to CD95-mediated apoptosis in BR97 cells. The expression levels of procaspase-3, -8 and of the adaptor protein FADD were not modified in cycloheximide-sensitized BR97 cells (data not shown).
Taken together these results suggest that resistance to CD95-induced apoptosis in BR97 cells is due at least in part to high level expression of apoptotic inhibitor c-FLIP. were electrophoresed on a 10% or 12% SDS-PAGE. c-FLIP was detected using specific antibody. Actin monoclonal antibody was used to check the loading.
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DISC formation in CD95-stimulated BR97 cells
We next analyzed formation of the DISC in BR97 cell line following CD95 stimulation. We immunoprecipitated either the unstimulated or the stimulated CD95 receptor and tested the associated FADD or caspase-8 by Western blot analysis. As shown in Figure 9a and b, the caspase-8 proenzyme, the caspase-8 p43 and p41 cleaved forms and FADD were detected at the DISC of CD95-stimulated BR97 cells. Therefore, in BR97 cells, caspase-8 is recruited to the DISC but, as previously shown, no activation of caspase-8 is observed following CD95 triggering. Since a high level of c-FLIP is constitutively present in BR97 cells, c-FLIP could be responsible for the absence of caspase-8 activation in CD95-stimulated BR97 cells. We therefore tested for the presence of c-FLIP at the DISC and, as shown in Figure 9c , c-FLIP associated with CD95 in a stimulation-dependent fashion. However, the full length c-FLIP was not detected at the DISC but only the p43-c-FLIP cleaved form. Furthermore, c-FLIP expression was substantially decreased in cycloheximide-treated cells with restored CD95-sensitivity mediated by caspase-8 and -3 activations. Taken together these results support the conclusion that in BR97 cell line c-FLIP interferes with caspase-8 activation at the DISC level and thus inhibits CD95-mediated apoptosis.
Discussion
Perturbations in B cell homeostasis (proliferation, differentiation or apoptosis), are implicated in the emergence of tumoral B cell clones. Defective cell death could be one underlying mechanism in lymphomagenesis and this possibility is supported by recent data from our laboratory 16 and others 41 indicating defective responses in CD95-mediated apoptosis in B cell non-Hodgkin's lymphomas. Indeed, of 40 B cell NHL, including mantle cell (MCL), lymphocytic cell (LCL), follicular (FL) and diffuse large cell lymphoma (DLCL), analyzed in our laboratory, all constitutively expressed varying levels of CD95 receptor but were completely resistant to CD95-mediated apoptosis. 16 In contrast, in normal B cells, CD95 expression and sensitivity to CD95-mediated apoptosis is highly dependent on the activation state of the cell. Most resting B cells express no or low levels of CD95 42, 43 and CD95 expression is upregulated after addition of lipopolysaccharide, interleukin-4 or CD40 engagement, rendering activated B cells susceptible to CD95-mediated apoptosis in the absence of antigen receptor engagement. 11, 44, 45 In order to study the mechanisms underlying resistance to CD95-mediated apoptosis in NHL, we used two new B lymphoma cell lines, B593 and BR97, derived in our laboratory from B-NHL. Despite significant levels of CD95 expression in both cell lines, B593 cells were found to be highly sensitive to CD95-mediated cell death, whereas BR97 cells were completely resistant. In this respect, the BR97 cell line is a particularly useful model for investigation of the mechanisms implicated in resistance to CD95-mediated apoptosis in B-NHL.
In an attempt to elucidate the origins of CD95-mediated apoptotic resistance in BR97, we firstly investigated the possibility of alterations in intracellular signalling pathways, specifically the functional status of caspases in the signalling cascade. Interestingly, BR97 cells were found to be incapable of achieving either caspase-8 or caspase-3 activation in response to CD95 stimulation while in B593 cells both caspases were activated normally. However the absence of caspase-8 and caspase-3 activation in BR97 cells was unlikely to result from abnormal caspases since both caspases could be activated following staurosporine treatment. In addition, the fact that protein synthesis inhibition in BR97 cells restored sensitivity to CD95-mediated apoptosis (and caspase-8 and caspase-3 activation), not only indicated that the CD95 pathway is intact in these cells but also raised the possibility that resistance to CD95-mediated apoptosis might be due to the presence of inhibitors blocking the CD95 signalling pathway.
In keeping with this, a high level of constitutive expression of the apoptotic inhibitor c-FLIP was observed in the CD95-resistant BR97 cell line compared to B593 and to other CD95-sensitive cell lines like Jurkat and Raji. Constitutive c-FLIP expression has been demonstrated in several cell lines sensitive to CD95-mediated apoptosis. 46 In these cell lines the expression level of c-FLIP was very low compared to the amount of caspase-8 and it has been suggested that c-FLIP inhibits CD95-mediated apoptosis only when expressed at high levels.
Here we show that, in BR97 cells, downregulation of c-FLIP expression level by protein synthesis inhibition strictly correlated with restored sensitivity to CD95-mediated apoptosis. Furthermore, we demonstrate that c-FLIP is recruited to the CD95 DISC in BR97 cells together with caspase-8 and FADD. We therefore propose that resistance to CD95-mediated apoptosis in BR97 cells results, at least in part, from constitutive high level expression of apoptotic inhibitor c-FLIP which impairs caspase-8 activation at the DISC level. Expression of c-FLIP has previously been reported in human T cells and in melanoma cell lines expressing CD95 and showing resistance to CD95-induced apoptosis. 33 To our knowledge, this is the first report of a lymphocyte cell line with endogenous c-FLIP expression and resistant to CD95-mediated apoptosis.
The apoptotic inhibitor Bcl-xL was also expressed at high levels in BR97 cells as compared to B593 cells and its expression was markedly decreased in the presence of cycloheximide (data not shown). However the role of Bcl-2/Bcl-xL family members in the CD95 signalling apoptotic pathway remains controversial. Reports range from no effect, [47] [48] [49] to substantial inhibition. [50] [51] [52] Increased Bcl-xL expression has been described to protect B cells 53 and peripheral T cells, 32 at least in part, from CD95-mediated apoptosis. Contradictory results about the inhibitory role of Bcl-2/Bcl-xL on the CD95 pathway may be due to the use of different cell types in these various studies. Indeed, recently, evidence for the existence of two distinct CD95 signalling pathways which are cell type specific has emerged. 31 In BR97 cells, c-FLIP may specifically interfere with caspase-8 activation whereas Bcl-xL may contribute to provide a level of resistance against other apoptotic stimuli. In keeping with this, BR97 cells were only moderately sensitive to staurosporine-induced apoptosis.
Furthermore, it will be interesting to investigate in CD95-resistant B-NHL the role of the Bruton's tyrosine kinase which inhibits formation of the DISC 54 and of other recently described cell death inhibitors, such as survivin 55 or the IAP family of antiapoptotic proteins. 56 Finally, another possible mechanism of resistance to CD95-mediated apoptosis could be the presence of alterations in the CD95 receptor itself. 57, 58 In the case of B cell NHL, one study has indicated a low frequency (3 to 6%) of CD95 alterations. 59 Likewise, alterations in other proteins from the DISC, like FADD, 60 or modifications in their caspase recruiting capacity leading to reduced DISC formation, could also confer protection against CD95-induced cell death in B cell NHL. 44 Although alterations other than resistance to cell death clearly participate in in vivo lymphoma growth, the precise identification of alterations concerning the apoptotic machinery would be of great value in elucidating lymphomagenesis and ultimately in the development of more effective therapeutic strategies.
